Creatine and Creatinine Metabolism - Physiological Reviews

July 2000 CREATINE AND CREATININE METABOLISM 1199
nylimidazo[4,5-b]pyridine in Salmonella typhimurium and isolated
rat hepatocytes. Chem Res Toxicol 7: 139–147, 1994.
591. MANABE S, KURIHARA N, WADA O, TOHYAMA K, AND ARA-
MAKI T. Formation of PhIP in a mixture of creatinine, phenylalanine
and sugar or aldehyde by aqueous heating. Carcinogenesis
13: 827–830, 1992.
592. MANABE S, SUZUKI H, WADA O, AND UEKI A. Detection of the
carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
(PhIP) in beer and wine. Carcinogenesis 14: 899–901, 1993.
593. MANFREDI JJ AND HORWITZ SB. Taxol: an antimitotic agent with
a new mechanism of action. Pharmacol Ther 25: 83–125, 1984.
594. MANTON DJ, LOWRY M, BLACKBAND SJ, AND HORSMAN A.
Determination of proton metabolite concentrations and relaxation
parameters in normal human brain and intracranial tumours.
NMR Biomed 8: 104–112, 1995.
595. MARESCAU B. Guanidino compound analysis as a complementary
diagnostic parameter for hyperargininemia: follow-up of guanidino
compound levels during therapy. Pediatr Res 27: 297–303,
1990.
596. MARESCAU B. Guanidino compounds in hyperargininemia. In:
Guanidino Compounds in Biology and Medicine, edited by P. P.
De Deyn, B. Marescau, V. Stalon, and I. A. Qureshi. London:
Libbey, 1992, p. 363–371.
597. MARESCAU B, DESHMUKH DR, KOCKX M, POSSEMIERS I,
QURESHI IA, WIECHERT P, AND DE DEYN PP. Guanidino compounds
in serum, urine, liver, kidney, and brain of man and some
ureotelic animals. Metabolism 41: 526–532, 1992.
598. MARESCAU B, NAGELS G, POSSEMIERS I, DE BROE ME, BE-
CAUS I, BILLIOUW J-M, LORNOY W, AND DE DEYN PP. Guanidino
compounds in serum and urine of nondialyzed patients
with chronic renal insufficiency. Metabolism 46: 1024–1031, 1997.
599. MARKIEWICZ W, WU SS, PARMLEY WW, HIGGINS CB, SIEVERS
R, JAMES TL, WIKMAN-COFFELT J, AND JASMIN G. Evaluation of
the hereditary Syrian hamster cardiomyopathy by 31 P nuclear
magnetic resonance spectroscopy: improvement after acute verapamil
therapy. Circ Res 59: 597–604, 1986.
600. MARTIN KJ, CHEN S-F, CLARK GM, DEGEN D, WAJIMA M, VON
HOFF DD, AND KADDURAH-DAOUK R. Evaluation of creatine
analogues as a new class of anticancer agents using freshly explanted
human tumor cells. J Natl Cancer Inst 86: 608–613, 1994.
601. MARTIN KJ, VASSALLO CD, TEICHER BA, AND KADDURAH-
DAOUK R. Microtubule stabilization and potentiation of taxol
activity by the creatine analogue cyclocreatine. Anti-Cancer
Drugs 6: 419–426, 1995.
602. MARTIN KJ, WINSLOW ER, AND KADDURAH-DAOUK R. Cell
cycle studies of cyclocreatine, a new anticancer agent. Cancer Res
54: 5160–5165, 1994.
603. MARTIN KJ, WINSLOW ER, O’KEEFE M, KHANDEKAR VS, HAM-
LIN A, LILLIE JW, AND KADDURAH-DAOUK R. Specific targeting
of tumor cells by the creatine analog cyclocreatine. Int J Oncol 9:
993–999, 1996.
604. MARUYAMA W, OTA A, TAKAHASHI A, NAGATSU T, AND NAOI
M. Food-derived heterocyclic amines, 3-amino-1,4-dimethyl-5Hpyrido[4,3-b]indole
and related amines, as inhibitors of monoamine
metabolism. J Neural Transm 41 Suppl: 327–333, 1994.
605. MASOOD E. Performance-enhancers pose dilemma for rule-makers.
Nature 382: 16, 1996.
606. MASSON S AND QUISTORFF B. Kinetics of creatine uptake in the
perfused mouse liver: a 31 P-nmr study of transgenic mice expressing
creatine kinase (CK BB) in the liver. Biochem J 303: 531–538,
1994.
607. MASTROROBERTO P, CHELLO M, DI TOMMASO L, AND
MARCHESE AR. The effects of creatine phosphate in experimental
myocardial infarction. Curr Ther Res 57: 552–558, 1996.
608. MATSUDA Y, WAKAMATSU N, INOUYE Y, UEDE S, HASHIMOTO
Y, ASANO K, AND NAKAMURA S. Purification and characterization
of creatine amidinohydrolase of Alcaligenes origin. Chem Pharm
Bull 34: 2155–2160, 1986.
609. MATSUMOTO M, FUJIWARA M, MORI A, AND ROBIN Y. Effet des
dérivés guanidiques sur la cholinacétylase et sur l’acétylcholinestérase
du cerveau du lapin. C R Soc Biol 171: 1226–1229,
1977.
610. MATSUMOTO M AND MORI A. Effects of guanidino compounds on
rabbit brain microsomal Na � -K � ATPase activity. J Neurochem
27: 635–636, 1976.
611. MATSUMOTO Y, KANEKO M, KOBAYASHI A, FUJISE Y, AND
YAMAZAKI N. Creatine kinase kinetics in diabetic cardiomyopathy.
Am J Physiol Endocrinol Metab 268: E1070–E1076, 1995.
612. MATSUOKA M, INOUE N, IGISU H, AND KOHRIYAMA K. Effects
of neurotoxins on brain creatine kinase activity. Environ Res 61:
37–42, 1993.
613. MATSUSHIMA T. Mechanisms of conversion of food components
to mutagens and carcinogens. In: Molecular Interrelations of
Nutrition and Cancer, edited by M. S. Arnott, J. van Eys, and
Y.-M. Wang. New York: Raven, 1982, p. 35–42.
614. MATTHEWS PM, BLAND JL, GADIAN DG, AND RADDA GK. A
31 P-NMR saturation transfer study of the regulation of creatine
kinase in the rat heart. Biochim Biophys Acta 721: 312–320, 1982.
615. MATTHEWS RT, FERRANTE RJ, KLIVENYI P, YANG L, KLEIN
AM, MUELLER G, KADDURAH-DAOUK R, AND BEAL MF. Creatine
and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol
157: 142–149, 1999.
616. MATTHEWS RT, YANG L, JENKINS BG, FERRANTE RJ, ROSEN
BR, KADDURAH-DAOUK R, AND BEAL MF. Neuroprotective effects
of creatine and cyclocreatine in animal models of Huntington’s
disease. J Neurosci 18: 156–163, 1998.
617. MAUTHE RJ, MARSCH GA, AND TURTELTAUB KW. Improved
high-performance liquid chromatography analysis of 32 P-postlabeled
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adducts
using in-line precolumn purification. J Chromatogr 679:
91–101, 1996.
618. MAUTHE RJ, SNYDERWINE EG, GHOSHAL A, FREEMAN SPHT,
AND TURTELTAUB KW. Distribution and metabolism of 2-amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in female rats and
their pups at dietary doses. Carcinogenesis 19: 919–924, 1998.
619. MAYSER W, SCHLOSS P, AND BETZ H. Primary structure and
functional expression of a choline transporter expressed in the rat
nervous system. FEBS Lett 305: 31–36, 1992.
620. MCAULIFFE JJ, PERRY SB, BROOKS EE, AND INGWALL JS. Kinetics
of the creatine kinase reaction in neonatal rabbit heart: an
empirical analysis of the rate equation. Biochemistry 30: 2585–
2593, 1991.
621. MCCARREY JR AND THOMAS K. Human testis-specific PGK gene
lacks introns and possesses characteristics of a processed gene.
Nature 326: 501–505, 1987.
622. MCCORD JM AND TURRENS JF. Mitochondrial injury by ischemia
and reperfusion. Curr Top Bioenerg 17: 173–195, 1994.
623. MCGUIRE DM, GROSS MD, ELDE RP, AND VAN PILSUM JF.
Localization of L-arginine-glycine amidinotransferase protein in
rat tissues by immunofluorescence microscopy. J Histochem Cytochem
34: 429–435, 1986.
624. MCGUIRE DM, GROSS MD, VAN PILSUM JF, AND TOWLE HC.
Repression of rat kidney L-arginine:glycine amidinotransferase
synthesis by creatine at a pretranslational level. J Biol Chem 259:
12034–12038, 1984.
625. MCGUIRE DM, TORMANEN CD, SEGAL IS, AND VAN PILSUM JF.
The effect of growth hormone and thyroxine on the amount of
L-arginine:glycine amidinotransferase in kidneys of hypophysectomized
rats. J Biol Chem 255: 1152–1159, 1980.
626. MCNALLY FJ AND VALE RD. Identification of katanin, an ATPase
that severs and disassembles stable microtubules. Cell 75: 419–
429, 1993.
627. MCNAUGHTON LR, DALTON B, AND TARR J. The effects of
creatine supplementation on high-intensity exercise performance
in elite performers. Eur J Appl Physiol 78: 236–240, 1998.
628. MEERT KL, DESHMUKH DR, MARESCAU B, DE DEYN PP, AND
SARNAIK AP. Effect of ammonium acetate-induced hyperammonemia
on metabolism of guanidino compounds. Biochem Med
Metab Biol 46: 208–214, 1991.
629. MEGLASSON MD, WILSON JM, YU JH, ROBINSON DD, WYSE
BM, AND DE SOUZA CJ. Antihyperglycemic action of guanidinoalkanoic
acids: 3-guanidinopropionic acid ameliorates hyperglycemia
in diabetic KKA y and C57BL6Job/ob mice and increases
glucose disappearance in rhesus monkeys. J Pharmacol Exp Ther
266: 1454–1462, 1993.
630. MEHTA HB, POPOVICH BK, AND DILLMANN WH. Ischemia in-